前收市價 | 0.1500 |
開市 | 0.1500 |
買盤 | 0.0000 |
賣出價 | 0.9000 |
拍板 | 15.00 |
到期日 | 2024-06-21 |
今日波幅 | 0.1500 - 0.1500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 474 |
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
The consensus price target hints at a 101.1% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.